|
Raising the bar for lower-risk myelodysplastic syndromes |
Jun 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
Dec 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
Sep 2019 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
May 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
|
Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia |
Mar 2023 |
International Journal of Hematology |
Aplastic Anemia |
|
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
Apr 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Rethinking clinical trial endpoints in myelodysplastic syndromes. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
